

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

AL

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/12, C07K 14/705, A61K 38/17, 47/00, 35/14, 48/00</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/19478</b> <b>(43) International Publication Date:</b> 22 April 1999 (22.04.99)
<b>(21) International Application Number:</b> PCT/US98/19794 <b>(22) International Filing Date:</b> 22 September 1998 (22.09.98)  <b>(30) Priority Data:</b> 60/061,589 10 October 1997 (10.10.97) US  <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US 60/061,589 (CON) Filed on 10 October 1997 (10.10.97)  <b>(71) Applicant (for all designated States except US):</b> THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Office of Technology Transfer, National Institutes of Health, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> SCHLOM, Jeffrey [US/US]; 10301 Sorrel Avenue, Potomac, MD 20854 (US). BARZAGA, Elene [US/US]; 512 Rutgers Street, Rockville, MD 20850 (US). ZAREMBA, Sam [US/US]; 243 Rollins Avenue #102, Rockville, MD 20852 (US).		<b>(74) Agents:</b> FEILER, William, S. et al.; Morgan & Finnegan, L.L.P., 345 Park Avenue, New York, NY 10154 (US).  <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> AGONIST AND ANTAGONIST PEPTIDES OF CARCINOEMBRYONIC ANTIGEN (CEA)  <b>(57) Abstract</b>  The present invention relates to the preparation and use of peptides that act as agonists and antagonists of human carcinoembryonic antigen (CEA). Agonists of the CEA peptide, CAPI, are disclosed and their utility in enhancing immune responses against CEA demonstrated.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

-1-

## AGONIST AND ANTAGONIST PEPTIDES OF CARCINOEMBRYONIC ANTIGEN (CEA)

FIELD OF THE INVENTION

The present invention relates to the preparation and use of peptides that can act as agonists and antagonists of human carcinoembryonic antigen (CEA). More specifically, the agonist peptide according to the present invention can be used as an immunogen, either alone, or in prime and boost protocols with other immunogens such as rV-CEA, for a variety of neoplastic conditions. These may include colorectal cancer, lung cancer, pancreatic cancer, and breast cancer. Thus, the present invention also relates to the production and use of vaccines against cancer. Peptide agonists according to the present invention can also be used to facilitate propagation of T cells, for example, from vaccinated patients, for adoptive transfer studies. Peptide antagonists according to the present invention find utility in suppressing autoimmune responses, such as those involving T cells, when such responses occur in vaccinated patients. Thus, the present invention also relates to the production and use of vaccines against autoimmune diseases, especially those mediated by lymphocytes and other antigen presenting cells.

BACKGROUND OF THE INVENTION

A major challenge of modern cancer immunotherapy is the identification of cytotoxic T lymphocyte (CTL) epitopes from defined tumor-associated antigens (TAA) that promote lysis of tumor cells. The majority of antigens on human cancers are not tumor specific and are overexpressed in malignant cells as opposed to cells of normal tissues.

-2-

Therefore, immunity to cancer in humans may rest mostly on the development of an effective immune response mainly directed to self-molecules qualitatively common to all cell types.

Human carcinoembryonic antigen (CEA) is a 180 kD glycoprotein expressed on the majority of colon, rectal, stomach and pancreatic tumors (1), some 50% of breast carcinomas (2) and 70% of lung carcinomas (3). CEA is also expressed in fetal gut tissue, and to a lesser extent on normal colon epithelium. The immunogenicity of CEA has been ambiguous, with several studies reporting the presence of anti-CEA antibodies in patients (4-7) while other studies have not (8-10). CEA was first described as a cancer specific fetal antigen in adenocarcinoma of the human digestive tract in 1965 (Gold, P. and Freeman, S.O. (1965) Exp. Med. 121:439-462). Since that time, CEA has been characterized as a cell surface antigen produced in excess in nearly all solid tumors of the human gastrointestinal tract. The gene for the human CEA protein has been cloned. (Oikawa et al (1987) Biochim. Biophys. Res. 142:511-518; European Application No. EP 0346710).

Recently, the first evidence was reported of a human CTL response to CEA (11). This CAP1 peptide showed the highest level of T2 cell binding among the various CEA peptides tested with stimulation of the T cells resulting in the generation of cytotoxic T cell lines. We have identified a 9-mer peptide, designated CAP1 (with the sequence YLSGANLNL) (SEQ. ID NO: 1), on the basis of binding to HLA-A2, and the ability to generate specific CTL from peripheral blood mononuclear cells (PBMC) from carcinoma patients immunized with a recombinant vaccinia

-3-

0 virus expressing CEA (rV-CEA). For example, peripheral  
blood lymphocytes (PBLs) from 5 patients showed signs of T  
cell response to CAP1 peptide after immunization with rV-  
CEA. Two other laboratories have since generated CAP1  
specific CTL in vitro employing peptide pulsed dendritic  
5 cells as antigen presenting cells (APC) (12). It has also  
recently been reported (13) that CAP1 specific CTL can be  
generated from PBMC from carcinoma patients immunized with  
the avipox recombinant ALVAC-CEA. Several groups have also  
10 reported the generation of anti-CEA antibodies and CEA  
specific proliferative T cell responses following  
immunization with either an anti-Id to an anti-CEA  
monoclonal antibody (MAb) (14), recombinant CEA protein  
(15), or rV-CEA (16).

15 Several investigators have introduced CTL to  
tumor associated and viral antigens by in vitro  
stimulation of PBMC with an immunodominant peptide. Recent  
work with the gp100 melanoma antigen (17-19), an HIV  
polymerase peptide (20) and the papilloma virus tumor  
20 antigen E6 (21) demonstrated enhanced immunogenicity after  
modifications to the peptide sequences. In these studies,  
replacements were at anchor positions and were intended to  
increase binding to murine or human MHC antigens. This  
25 approach was based on a demonstrated correlation between  
immunogenicity and peptide binding affinity to class I MHC  
(major histocompatibility complex) molecules for viral  
antigen epitopes (22).

30 Previous investigators have also worked with  
fragments of CEA. Thus, Shively (1989), in a European  
patent publication (EP No. 0343946 A2) reports a number of  
CEA fragments that include a unique epitope (as defined by  
35

-4-

its reactivity with an antibody). The latter CEA fragment is 177 amino acid residues long and contains the 9-mer sequence of CAP1. However, no shorter CEA fragments that include the CAP1 sequence were described.

In sum, the use of rV-CEA alone as an agent for boosting the CEA-specific immune response of rV-CEA suffers from the drawback of stimulating an immune response to vaccinia virus. However, the novel combination of rV-CEA and CAP1 suggested itself to us as a "second generation protocol" for the treatment of cancer patients.

It is an accepted principle that when an immunogenic peptide is modified in a conserved manner (e.g., a hydrophobic amino acid is substituted with a hydrophobic amino acid) the modified peptide is likely to have similar immunogenic activity based upon the maintenance of the molecule's shape, charge and hydrophobic character.

More specifically, a study by Madden (33) has identified specific amino acid preferences in peptides for MHC-complexing, a precursor step to T cell recognition. Madden as well as other investigators (31) suggest that specific amino acid positions in peptides are available for T cell recognition.

Skipper et al. (40) describes the identification and characterization of a naturally-occurring peptide epitope of tyrosinase, wherein the peptide sequence differs from that which is predicted from the DNA. This modified peptide is recognized by tyrosinase-specific human cytotoxic T-lymphocytes ("CTL") more effectively than the direct translation product and is the only one of the two peptides to be presented by HLA-A2.1 molecules on

-5-

the cell surface. The modification is a substitution of an asparagine with an aspartic acid. The authors propose that the asparagine is N-glycosylated in the endoplasmic reticulum during protein synthesis and is deamidated post-translationally.

5 In the case of CAP1, the primary and secondary anchors at positions 2, 9, and 1 are already occupied by preferred amino acids and so a different approach was taken to improve peptide immunogenicity by attempting to enhance its ability to bind to the TCR. It appeared to us  
10 that by altering amino acid residues expected to contact the TCR one could generate an analog of CAP1 with substitutions at non-MHC anchor positions. Such an analog might then represent a T cell enhancer agonist capable of stimulating CTL more efficiently than the native peptide.  
15 Previous results supported the concept that some peptide analogs could act as T cell antagonists by inhibiting responses to the antigenic peptide (23-29). Such inhibition was shown to be TCR specific and could not be  
20 explained by competition for peptide binding to the MHC protein. Analogously, a peptide enhancer agonist would be an analog that increased the effector function without accompanying increases in MHC binding. We therefore sought  
25 to increase CAP1 immunogenicity by analyzing panels of analogs containing single amino acid substitutions to residues we predicted would interact with the T cell receptor (TCR) of CAP1-specific CTL. The present invention relates to the construction of a novel T cell enhancer  
30 agonist for the CAP1 peptide, the first such example for a human CTL epitope.

-6-

SUMMARY OF THE INVENTION

0  
The present invention relates to the  
identification of peptides which are single or double  
amino acid changes from the CAP-1 peptide sequence. The  
CAP-1 peptide has been identified as a highly immunogenic  
5 epitope of the carcinoembryonic antigen (referred to  
herein as "CEA"), which is capable of stimulating CEA-  
specific cytolytic T-cell ("CTL") responses. CEA is a cell  
surface antigen found in abundance on several types of  
10 cancer cells. Thus, peptides of CEA capable of stimulating  
a cytolytic CTL response, such as CAP-1 are potential  
immunogens for use in cancer immunotherapy.

Some of the peptides of the present invention  
15 are agonists of CAP-1 and CEA; that is, they facilitate  
the interaction between the MHC-complex of the antigen-  
presenting cell and the T-cell receptor ("TCR") complex of  
the T-cell. Thus, these peptides can serve as immunogens  
to treat and/or vaccinate patients with CEA-expressing  
20 cancers. Also, these peptides may be used to stimulate T-  
cells in culture for adoptive transfer of T-cells to  
cancer patients. Four such peptides have amino acid  
sequences:

- 25 (1) YLSGADLNL (Agonist CAP1-6D) (SEQ. ID NO:  
2);  
(2) YLSGADINL (Agonist CAP1-6D, 7I) (SEQ. ID  
NO: 3);  
(3) YLSGANINL (Agonist CAP1-7I) (SEQ. ID NO:  
30 4); and  
(4) YLSGACLNL (agonist CAP1-6C) (SEQ. ID NO.:  
5).

The underlined amino acids identify the amino acids

35



-7-

changes from the CAP-1 peptide sequence. Peptides CAP1-6D and CAP1-6D, 7I are especially preferred peptides according to the present invention and have enhanced activity as compared to CAP-1 activity. Peptides CAP1-7I and CAP1-6C have activity similar to CAP-1.

Other peptides according to the present invention function as antagonists of CEA; that is, they reduce or eliminate CEA-specific T-cell activation and killing which occur through interactions of the MHC-peptide complex and TCR complex.

The present invention encompasses kits comprising an agonist peptide and a vector comprising a gene encoding CEA or a recombinantly produced CEA protein. Moreover, the kit may include an immunostimulatory molecule.

The present invention also encompasses kits comprising an antagonist peptide alone or in combination with an immunosuppressive agent.

Another object of the present invention is a pharmaceutical composition comprising one or more agonist peptides alone or in combination with an immunostimulatory molecule and a pharmaceutically acceptable carrier.

Another object of the present invention is a pharmaceutical composition comprising one or more antagonist peptides alone or in combination with an immunosuppressing agent and a pharmaceutically acceptable carrier.

The present aspect of the present invention is a nucleic acid sequence encoding at least one agonist peptide or encoding at least one antagonist peptide.

Another aspect of the invention is a vector

-8-

comprising a nucleic acid sequence encoding at least one agonist peptide or a nucleic acid sequence encoding at least one antagonist peptide and host cells comprising such vectors.

Another aspect of the present invention relates to the use of these peptides in cancer immunotherapy. The agonist peptides are useful in stimulating a cytolytic immune response to CEA, resulting tumor reduction and/or prevention. Accordingly, the present invention also relates to a method of treating cancer patients with the peptides as well as a cancer vaccine. The antagonist peptides are useful in methods of controlling autoimmune response to CEA or CAP-1.

Yet another aspect of the present invention is an agonist-pulsed antigen presenting cell.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1A-1D:** Effect of single amino acid substitutions in CEA CAP1 peptide on lysis by CEA CTL T-Vac8 C1R-A2

cells were labeled with  $^{111}\text{In}$  and incubated for 1 hour in round bottom wells (2,000/well) with each substituted peptide at 1 (solid), 0.1 (open) and 0.01 (hatched)  $\mu\text{g/ml}$ . T-Vac8 CTL were added at E:T=1.45:1 and isotope release was measured after 4 hours. Spontaneous release was determined for each peptide at 1  $\mu\text{g/ml}$ . All assays were performed in triplicate. Figures 1A-1D depict substitutions at positions p5 through p8, respectively. Amino acids are designated by the single letter code; the amino acid encoding the native CAP1 sequence is indicated in each figure and along the right-hand margin.

**Figure 2A and 2B:** CAP1 and analogs show different sensitivity to CEA CTL T-Vac8 cytotoxicity Figure 2A T2

-9-

- and Figure 2B C1R-A2 target cells were labeled with  $^{51}\text{Cr}$  and incubated in round-bottomed 96 well plates (10,000/well) with CAP1 (●) or substituted peptides CAP1-6D (□) or CAP1-7I (◇) at the indicated concentrations. After 1 hour, T-Vac8 CTL were added at E:T=2.5:1 and isotope release was determined after 4 hours. All assays were done in triplicate. NCA571 (Δ) is a 9-mer peptide obtained after optimal alignment of CEA with the related gene NCA (11).
- Figure 3: Effect of single amino acid substitutions in CAP1 peptide on binding to and stability of HLA-A2 complexes** T2 cells were collected in serum free medium then incubated overnight ( $10^6$  well) with peptides CAP1(●), CAP1-6D (□), or CAP1-7I (◇) at the indicated concentrations. Cells were collected and assayed for cell surface expression of functional HLA-A2 molecules by staining with conformation sensitive MAb BB7.2, HLA specific antibody W6/32 (not shown) and isotype control Ab MOPC-195 (not shown). Mean fluorescent intensity was determined on a live, gated cell population. Figure insert: Cells were incubated with peptide at 100  $\mu\text{g/ml}$  overnight, then washed free of unbound peptide and incubated at 37°C. At the indicated times, cells were stained for the presence of cell surface peptide-HLA-A2 complexes. The error bars indicate SEM for two experiments.
- Figure 4A and 4B: CTL generated from apparently healthy individuals with CAP1-6D peptide recognize CAP1 and CAP1-6D** CTL lines (designated T-N1 and T-N2) were generated with CAP1-6D and were assayed for peptide specificity. T-

-10-

N1 was assayed after 5 cycles of stimulation at an effector to target ratio of 20:1 (Figure 4A). T-N2 was assayed after 10 cycles at an effector to target ratio of 15:1 (Figure 4B).  $^{51}\text{Cr}$ -labeled C1R-A2 targets (5,000/well) were incubated with the indicated amount of CAP1 (●) or CAP1-6D (□) peptide. After 4 hours the amount of isotope release was determined in a gamma counter. Values were determined from triplicate cultures.

**Figure 5A and 5B:** CAP1-6D, but not CAP1 generated T cell lines from apparently healthy donors recognize tumor cells expressing endogenous CEA CAP1-6D generated T-N2 CTL (Figure 5A) and T cells generated with native CAP1 (Figure 5B), were assayed after 9 cycles of in vitro stimulation against tumor targets SW480 and SW1463 (CEA<sup>+</sup>, HLA-A2<sup>+</sup>, ● and ▲ respectively), SKmel24 (CEA<sup>-</sup>, -A2<sup>+</sup>, □) and K562 (◇). Tumor cells were cultured for 72 hours in the presence of  $\gamma$ -IFN to up regulate HLA. Cells were trypsinized and labeled with  $^{51}\text{Cr}$  and incubated (5,000 cells/well) with T-N2 CTL at increasing effector to target ratios. Cultures were incubated for 4 hours and the amount of isotope release determined in a gamma counter. Values were determined from triplicate cultures.

**Figure 6:** MHC-class 1 A2.1 restriction of CTL line (T-N2) derived from CAP1-6D agonist CTL line T-N2 was used as an effector for the human colon carcinoma SW837 target cell. SW837 is CEA positive and HLA-A2.1 negative. SW837 were infected at an MOI of 10:1 with either a recombinant vaccinia containing the A2.1 transgene (■) or wild type vaccinia (Δ).

**Figure 7A and 7B:** CTL generated with CAP1-6D lyse CEA positive, HLA-A2 positive tumors: Effect of IFN

-11-

upregulation The T-N1 CTL generated with CAP1-6D were  
assayed against various tumor cell lines: SW480 (CEA<sup>+</sup> and  
HLA-A2<sup>+</sup> ●), SW1116 (CEA<sup>+</sup> but -A2<sup>-</sup>, □) and CaOV3 (CEA<sup>+</sup> but  
-A2<sup>+</sup>, ◇). Tumor cells were cultured 72 hours in the  
absence (Figure 7A) or presence (Figure 7B) of  $\gamma$ -IFN,  
trypsinized and labeled with <sup>51</sup>Cr then incubated (5,000  
cells/well) with T-N1 CTL at increasing effector to target  
ratios. Cultures were incubated for 4 hours and the amount  
of isotope release determined in a gamma counter. Values  
were determined from triplicate cultures.

#### DETAILED DESCRIPTION OF THE INVENTION

The invention is an peptide agonist of the  
native CEA epitope, CAP-1 (SEQ. ID NO: 1), as well as  
antagonists of SEQ. ID NO: 1. The agonist is  
characterized by its ability to elicit antigen specific  
cytotoxic T lymphocytes which inhibit the growth or kill  
carcinoma cells expressing CEA or CEA epitopes. An  
antagonist of the present invention serve to inhibit or  
prevent CEA specific immune responses. Such peptides may  
be used to shut off any unwanted immune responses to CAP-1  
or CEA. One example for such use of an antagonist is to  
control any possible autoimmune response that may occur  
during cancer immunotherapy, where the therapy has killed  
off tumor cells and begins to attack normal cells  
expressing CEA. In accordance with the present invention  
an antagonist would advantageously prevent extensive  
damage to normal tissue.

The peptide agonists of the present invention  
comprise about 8-13 amino acids, preferably 9-10 amino  
acids. In a preferred embodiment, the agonist peptide of  
the present invention comprises at least one amino acid

35

-12-

substitution at a non-anchor position. In one embodiment, the agonist comprises a sequence with a substitution at position 6 compared to the native CAP-1 (SEQ. ID NO: 1). In another embodiment the agonist comprises a sequence with an amino acid substitution at position 7 compared to the native CAP-1 (SEQ. ID NO: 1). In yet another embodiment, the agonist comprises a sequence with an amino acid substitution at position 6 and at position 7 compared to the native CAP-1. The substituted amino acid serves to enhance the interaction of the TCR complex on the cytotoxic T lymphocytes with the peptide- MHC antigen ligand complex. Such enhanced interaction results in greater effector function by the cytotoxic T lymphocytes.

An example of a substitution includes Asp and Cys at position 6 or an Ile at position 7.

In one embodiment, the peptide agonist comprises the following amino acid sequence:

Amino Acid

<u>Position</u>	1	2	3	4	5	6	7	8	9
-----------------	---	---	---	---	---	---	---	---	---

Native CAP-1

Peptide	Y	L	S	G	A	N	L	N	L (SEQ. ID NO: 1)
---------	---	---	---	---	---	---	---	---	-------------------

Agonist	Y	L	S	G	A	<u>D</u>	L	N	L (SEQ. ID NO: 2)
---------	---	---	---	---	---	----------	---	---	-------------------

Agonist	Y	L	S	G	A	<u>D</u>	<u>I</u>	N	L (SEQ. ID NO: 3)
---------	---	---	---	---	---	----------	----------	---	-------------------

Agonist	Y	L	S	G	A	N	<u>I</u>	N	L (SEQ. ID NO: 4)
---------	---	---	---	---	---	---	----------	---	-------------------

Agonist	Y	L	S	G	A	<u>C</u>	L	N	L (SEQ. ID NO: 5)
---------	---	---	---	---	---	----------	---	---	-------------------

The agonist peptide of the present invention may be obtained by recombinant DNA technology or by chemical peptide synthesis.

The agonist peptide may be formulated into a pharmaceutical composition in combination with a pharmaceutically acceptable carrier for use as an

-13-

immunogen in a mammal, preferably a human. The composition may further comprise one or more other constituents to enhance the immune response which include but are not limited to immunostimulatory molecules such as interleukin 2, interleukin 6, interleukin 12, interferon gamma, tumor necrosis factor alpha, GM-CSF, B7.1, B7.2, ICAM-1, LFA-3, CD72, and cyclophosphamide.

The agonist peptide is administered to a mammal in an amount effective in generating a CEA specific immune response, preferably a cellular immune response. The efficacy of the mutant *ras* peptide as an immunogen may be determined by *in vivo* or *in vitro* parameters as are known in the art. These parameters include but are not limited to antigen specific cytotoxicity assays, regression of tumors expressing CEA or CEA epitopes, inhibition of cancer cells expressing CEA or CEA epitopes, production of cytokines and the like.

At least one or more agonist peptides may be administered in a dose of about 0.05 mg to about 10 mg per vaccination of the mammal, preferably about 0.1 mg to about 5 mg per vaccination. Several doses may be provided over a period of weeks as indicated. In one embodiment a dose is provided every month for 3 months. The agonist peptide may be administered alone or in combination with adjuvants, incorporated into liposomes (U.S. Patent Nos. 5,643,599; 5,464,630; 5,059,421; 4,885,172), with cytokines, biological response modifiers, or other reagents in the art that are known to enhance immune response. Adjuvants include but are not limited to RIBI Detox™, QS21, alum and incomplete Freund's adjuvant. In one embodiment, the mutant *ras* peptide is administered in

-14-

combination with Detox™ (RIBI Immunochem Research,  
Hamilton, MT). RIBI Detox™ contains as active  
ingredients the cell wall skeleton from *Mycobacterium*  
*phlei* and monophosphoryl lipid A from *Salmonella minnesota*  
R595 prepared as an oil-in-water emulsion with squalene  
and tween 80.

The agonist peptides may also be conjugated to  
helper peptides or to large carrier molecules to enhance  
the immunogenicity of the peptide. These molecules  
include but are not limited to influenza peptide, tetanus  
toxoid, tetanus toxoid CD4 epitope, *Pseudomonas* exotoxin  
A, poly-L-lysine, a lipid tail, endoplasmic reticulum (ER)  
signal sequence and the like.

The peptides of the present invention may also  
be conjugated to an immunoglobulin molecule using art  
accepted methods. The immunoglobulin molecule may be  
specific for a surface receptor present on tumor cells but  
absent or in very low amounts on normal cells. The  
immunoglobulin may also be specific for a specific tissue.  
Such a peptide-immunoglobulin conjugate allows for  
targeting of the peptide to a specific tissue and/or cell.

Another effective form of the agonist peptide  
for generating an peptide specific immune response in a  
mammal is an agonist peptide-pulsed antigen presenting  
cell. The antigen presenting cells include but is not  
limited to dendritic cells, B lymphocytes, monocytes,  
macrophages and the like. In a preferred embodiment, the  
agonist peptide-pulsed antigen presenting cell is a  
dendritic cell.

The invention also provides a method of  
generating CEA and agonist peptide specific cytotoxic T



-15-

lymphocytes *in vivo* or *in vitro* by stimulation of lymphocytes from a source with an effective amount of a agonist alone or in combination with a immunostimulatory molecule and/or adjuvant or in a liposome formulation. The sources of lymphocytes include but are not limited to peripheral blood, tumor tissues, lymph nodes and effusions such as pleural fluid or ascites fluid and the like.

The CEA and agonist peptide specific cytotoxic T lymphocytes of the present invention are immunoreactive with CEA agonist or peptide. The cytotoxic T lymphocytes inhibit the occurrence of tumor cells and cancer and inhibit the growth or kill expressing tumor cells expressing CEA or epitopes thereof or agonist expressing tumor cells. The cytotoxic T lymphocytes, in addition to being antigen specific, are MHC class I restricted. In one embodiment the cytotoxic T lymphocytes are MHC class I HLA-A2 restricted. The cytotoxic T lymphocytes have a CD8<sup>+</sup> phenotype.

Selected patients bearing carcinoma cells expressing CEA or CEA epitopes are vaccinated subcutaneously up to three times at monthly intervals with DETOX<sup>TM</sup> adjuvant admixed with the appropriate peptide agonist may also be vaccinated carcinoma patients with autologous peripheral blood mononuclear cells pre-pulsed ex vivo with a peptide agonist alone or in combination with a peptide agonist. Anti-CEA T cell responses are evaluated as measured by proliferation assays.

Vaccination with CEA agonist peptides of the present invention induces highly specific and systemic anti-CEA cellular immune responses. Moreover, the development of such MHC class I-restricted agonist peptides has important

-16-

o implications for both active (i.e., vaccination) and passive (i.e., ex vivo expansion for cellular adoptive transfer) immunotherapies, which may be used for the induction and propagation of specific CD8<sup>+</sup> CTL responses in cancer patients.

5 Patients with solid tumors expressing CEA or epitopes thereof, including but not limited to colon cancer, lung cancer, pancreas cancer, endometrial cancer, breast cancer, thyroid cancer, melanoma, oral cancer, laryngeal cancer, seminoma, hepatocellular cancer, bile  
10 duct cancer, acute myeloblastic leukemia, basal cell carcinoma, squamous cell carcinoma, prostate cancer and the like benefit from immunization with the agonist peptides. Patients amenable to treatment using the  
15 agonist peptides of the present invention are those patients having tumors with CEA or CEA epitopes.

Peptides may be chemically synthesized under GMP conditions and purified by HPLC to >95% purity and  
20 lyophilized. Pharmaceutical compositions are formulated by reconstituting the peptide with a pharmaceutically acceptable carrier such as sodium chloride. In one example, each milliliter of solution contains 1500 µg of a  
25 agonist peptide plus 9.0 mg sodium chloride.

When the agonist peptide is administered with an adjuvant it is desirable to mix the peptide with the adjuvant shortly before administration to a patient.

The agonist peptide may be administered to a  
30 patient by various routes including but not limited to subcutaneous, intramuscular, intradermal, intraperitoneal, intravenous and the like. In one embodiment the agonist peptide is administered subcutaneously. The peptide may  
35

-17-

be administered at one or more sites to a patient. In one embodiment, the peptide, alone or in combination with an adjuvant, is administered into three sites subcutaneously, over the deltoids, the thighs and the abdomen.

In another method of generating an immune response, agonist peptide-pulsed antigen presenting cells are administered to the patient in an amount effective to generate an antigen specific immune response. The antigen presenting cells include but are not limited to dendritic cells, B lymphocytes, monocytes, macrophages and the like. In one embodiment, dendritic cells are isolated from a patient by methods described in Romani, N. et al (1994). The isolated dendritic cells are cultured *in vitro* with an agonist peptide for a period of about 0.5 to about 3 hours and washed to remove non-bound peptide. The agonist peptide-pulsed dendritic cells are transferred back into the patient at a concentration of about  $10^6$  to about  $10^9$  dendritic cells. Such a concentration is effective in generating an immune response in the patient including the generation of agonist peptide specific cytotoxic T lymphocytes which are able to inhibit the growth or kill tumor cells.

The criteria for determining an anti-tumor response in the immunized patient is as follows:

1. Complete Remission (CR): Complete disappearance of all evidence of tumor and return of abnormal tests to normal levels for a minimum of 4 weeks.

2. Partial Response (PR): Decrease by at least 50% in the sum of the products of the perpendicular diameters of all measured lesions in the absence of progression of any lesion nor the appearance of any new

-18-

lesions for at least 4 weeks.

3. Stable Disease (SD): Change in measurable disease too small to meet the requirements for partial response or progression and the appearance of no new lesions for a period of at least 12 weeks. There may be no worsening of symptoms.

4. Progressive Disease (PD) or Relapse: Any one of the criteria below must be met to be considered progressive disease:

Development of any new area of malignant disease (measurable or palpable),

Increase (>25%) in any pretreatment area of measurable malignant disease.

The immunological response to immunization with the agonist peptides are assessed by in-vitro T cell proliferation assay and/or by in-vitro T cell cytotoxic assay before and after vaccination.

The present invention includes *in vitro* immunization for T cell proliferation and generation of cytotoxic T cell lines to the tumor specific agonist peptide. *In vitro* cultivation of peptide specific T cells from peripheral blood mononuclear cells (PBMC), lymph node tissue (LNT), or tumor infiltrating lymphocytes (TIL) with agonist peptide and IL-2 generates CEA and agonist peptide specific T cells. These T cells are tested for cytotoxicity against agonist peptide primed APC (autologous EBV transformed B cells or autologous tumor cells) has described herein. Generated T cell clones are characterized phenotypically by flow cytometry for express of CD3, CD4, and CD8. Agonist peptide specific cytotoxic lymphocytes may be adoptively transferred to a patient in

-19-

- order to inhibit or kill CEA or CEA epitopes expressing tumor cells. Patients may then be reimmunized with agonist peptide preferably in adjuvant.

Generally, between about  $1 \times 10^5$  and  $2 \times 10^{11}$  cytotoxic T cells per infusion are administered in, for example, one to three infusions of about 200 to about 250 ml each over a period of 30 to 60 minutes. After completion of the infusions, the patient may be treated with a biological response modifier such as interleukin 2 (IL-2). In the case of IL-2, recombinant IL-2 is administered intravenously in a dose of 720,000 IU per kilogram of body weight every eight hours. After adoptive transfer of the antigen specific cytotoxic T cells into the patient, the patient may be additionally treated with the agonist peptide used to prime the cytotoxic T cells, to further expand the T cell number *in vivo*.

The invention encompasses a DNA sequence and variants thereof which encode an agonist peptide.

In one embodiment the DNA sequence encoding the agonist peptide is a variant of the DNA sequence comprising:

TAC CTT TCG GGA GCG AAC

Tyr Leu Ser Gly Ala Asn

CTC AAC CTC (SEQ. ID No: 6)

Leu Asn Leu (SEQ. ID No: 1).

One variant of SEQ. ID No: 6 includes but is not limited to a codon ATC (Ile) in place of the codon, CTC (Leu at position 7). Another variant of SEQ. ID No: 6 includes but is not limited to a codon, TGT (Cys) in place of the codon, AAC (Asn at position 6).

-20-

In another embodiment, the DNA sequence encoding the agonist peptide comprises:

TAC CTT TCG GGA GCG GAC  
Tyr Leu Ser Gly Ala Asp

5 CTC AAC CTC (SEQ. ID No: 7)  
Leu Asn Leu (SEQ. ID No: 2)  
and variants thereof.

In yet another embodiment, the DNA sequence encoding the agonist peptide comprises:

10 TAC CTT TCG GGA GCG GAC  
Tyr Leu Ser Gly Ala Asp

ATC AAC CTC (SEQ. ID No: 8)  
15 Ile Asn Leu (SEQ. ID No: 3)  
or variants thereof.

Included in the ambit of the invention are conservative substitutions based on codon degeneracy provided the modification results in a functionally equivalent agonist peptide or a peptide with enhanced immunogenicity.

The invention further provides vectors and plasmids comprising a DNA sequence encoding an agonist peptide. The vectors include but are not limited to E. coli plasmid, a Listeria vector and recombinant viral vector. Recombinant viral vectors including but not limited to orthopox virus, avipox virus, capripox virus, suipox virus, vaccinia, baculovirus, human adenovirus, SV40, bovine papilloma virus, and the like comprising the DNA sequence encoding an agonist peptide.

Recombinant agonist peptide can be obtained

-21-

using a baculovirus expression system in accordance with the method of Bei et al J. Clin. Lab. Anal. 9:261-268 (1995). Recombinant viral vectors can be constructed by methods known in the art such as U.S. Patent No. 5,093,258; WO96/10419 Cepko et al Cell 37:1053-1062 (1984); Morin et al Proc. Natl. Acad. Sci USA 84:4626-4630 (1987); Lowe et al Proc. Natl. Acad. Sci USA 84:3896-3900 (1987); Panicali & Paoletti, Proc. Natl. Acad. Sci USA 79:4927-4931 (1982); Mackett et al, Proc. Natl. Acad. Sci USA 79:7415-7419 (1982); WO 91/19803; Perkus et al Science 229:981-984 (1985); Kaufman et al Int. J. Cancer 48:900-907 (1991); Moss Science 252:1662 (1991); Smith and Moss BioTechniques Nov/Dec, p. 306-312 (1984); U.S. Patent No. 4,738,846; Sutter and Moss Proc. Natl. Acad. Sci USA 89:10847-10851 (1992); Sutter et al Virology (1994); and Baxby and Paoletti Vaccine 10:8-9 (1992).

Host cells which may express the DNA encoding the agonist peptide carried by vectors or plasmids are prokaryotic and eukaryotic host cells and include but are not limited to E. coli, Listeria, Bacillus species, COS cells, Vero cells, chick embryo, fibroblasts, tumor cells, antigen presenting cells and the like. When the host cell is an antigen presenting cell, the host cell is an antigen presenting cell, the host cell should additionally express an MHC class I molecule.

We recently reported (11) evidence of CTL responses to CEA in patients immunized with rV-CEA. The 9-mer peptide CAP1 was employed to expand CTL in vitro because of: (a) its strong binding to HLA-A2, and (b) its non-identity to other members of the CEA gene family expressed on normal tissues. CTLs were generated from

-22-

post-immunization PBMC of patients while preimmunization blood of the same patients failed to proliferate. In addition, CAP1 pulsed dendritic cells stimulated in vitro growth of -A2 restricted CTL from peripheral blood of unimmunized cancer patients (12). Finally when CTL were generated in vitro by stimulation with dendritic cells encoding full-length CEA mRNA, cytotoxicity against CAP1 was higher than activity against six other -A2 binding CEA peptides (S. Nair and E. Gilboa, personal communication or unpublished observation). Such results encourage the notion that CAP1 is an immunodominant epitope of the CEA molecule.

The present invention is intended to improve the immunogenicity of the CAP1 peptide by introducing amino acid substitutions at non-anchor positions to form the agonist peptides of the present invention. When using T-Vac8 CTL as an effector, the analog CAP1-6D sensitized target cells for lysis far better than CAP1 itself. Further studies showed that cytolytic activity of a second -A2 restricted, CAP1 specific CTL, T-Vac24, was as good or greater with CAP1-6D than with CAP1. These demonstrations of enhanced reactivity could not be explained by improved presentation by class I MHC. Finally, CAP1-6D could be used to stimulate CTL in vitro from PBMC of both carcinoma patients and normal donors. Prior to the present invention, attempts to stimulate anti-CAP1 CTL from normal donors using this same methodology have been unsuccessful. The present invention relates to stimulation of normal donors with CAP1-6D as opposed to native CAP1 where stimulation with the native sequence failed to produce specific cytotoxic activity. In contrast, stimulation with



-23-

6 CAP1-6D produced several CTL with specific anti-CAP1  
peptide reactivity as well as anti-tumor reactivity.  
Thus, the analog peptide CAP1-6D is capable of selecting a  
population of CAP1 specific human CTL more efficiently  
than native CAP1. Such an agonist might find applications  
5 in the design of T cell directed vaccines against  
CEA-expressing carcinoma.

The present invention also relates to the more  
efficient generation and expansion of tumor specific T  
10 cells for adoptive immunotherapy. In recent years, much  
progress has been achieved in characterizing the tumor  
associated antigen peptides that can be presented to CTL  
by class I HLA antigens. In instances where mutations  
generate neo-antigens such as point mutated ras (35, 36),  
15 p53 (37, 38) or  $\beta$ -catenin (39) vaccination strategies  
target the novel sequence under the assumption that the  
immune system is not "tolerant" to an antigen it has never  
seen. More recently it has been proposed that neo-antigens  
20 may also arise through post-translational deamidations  
(29, 40). However, in many instances the intended targets  
of tumor therapy are not neoantigens but rather normal  
oncofetal or differentiation antigens that are  
overexpressed or ectopically expressed by malignant cells.  
25 Such is the case for CEA (41). In such situations, models  
invoking "tolerance" predict that the immune system has  
encountered these antigens and is less able to respond to  
them. This classical picture has been challenged in recent  
30 years by numerous reports of immunity elicited to  
overexpressed differentiation antigens, oncogenes, and  
tumor suppressor genes (37, 38, 42-44). Nonetheless, it  
is often experimentally difficult to generate and expand T

-24-

cells with desired anti-tumor activity and it is therefore desirable to devise new strategies for generating CTL.

Some class II binding-peptides have been described in which substitutions enhance responses of murine and human Th clones without increasing the binding to class II antigens (29, 45-47). Among human class I peptides, however, the only substitutions described for the generation of CTL were those that increase binding to HLA (17-20). The substitutions in those studies were directed to residues at the primary or secondary anchor positions that define the binding motifs to class I MHC antigens. Even substitutions directed to a non-anchor position (19) achieved their enhancing effect by increasing binding to HLA-A2. The analog CAP1-6D in the present report represents what appears to be a different class of substituted CTL peptides, agonists that enhance recognition of the peptide-MHC ligand by the T cell receptor and produce greater effector function without increases in binding. To our knowledge this is the first such enhancer agonist peptide described for a human CTL.

The increased lytic susceptibility of targets in the presence of CAP1-6D is unlikely to be due to better antigen presentation. Binding experiments show that HLA-A2 presents the native CAP1, and the analogs CAP1-6D and CAP1-71 approximately equally. Another possibility is that CAP1-6D shows increased activity because it is presented by more than one allele and T-Vac8 is promiscuous towards peptide-MHC complexes. However, T-Vac8, T-Vac24, and CTL derived from nonimmunized patients showed better lysis with CAP1-6D. Since HLA-A2 is the only class I MHC on the targets employed, the improved

-25-

lysis cannot be accounted for by recruitment of another class I MHC.

Since anti-CAP1 CTL from multiple donors demonstrate agonist cross reactivity it is possible that CAP1-6D could be used to stimulate growth of CTL from numerous -A2 individuals. We are encouraged by the quite distinct differences between T-Vac8 and T-Vac24 in magnitude of response to the agonist; this implies that each effector utilizes different TCR gene segments and that nonetheless they can recognize both the native sequence and the CAP1-6D substitution. The ability of CAP1-6D to act as an agonist with T cells expressing different T cell receptors clearly magnifies its therapeutic potential. Thus, the present invention also relates to stimulation with the agonist and subsequent generation of T cells that recognize the normal sequence in non-immunized individuals. Such individuals have presumably never encountered the modified sequence and since the agonist is more efficient at triggering a T cell response, such agonists might be capable of selecting CTL more readily than immunogens based on the native sequence.

For peptide-derived CTL to be useful therapeutic reagents it is essential to demonstrate that they can lyse tumor cells that express endogenous antigen (48, 49). Previously (11), we had shown that tumor cells process CEA and present antigens recognized by CTL generated by stimulation with CAP1. In accordance with the present invention, CTL grown from the normal donors by stimulation with CAP1-6D are also capable of recognizing allogeneic CEA-positive, HLA-A2 positive tumor cells. These T cells fail to recognize -A2 negative tumor cells or -A2 positive

-26-

cells that lack CEA expression.

We have also shown that CTL selected with the CAP1-6D agonist can be maintained subsequently by stimulation with the native CAP1 sequence. This is an important finding since CTL in patients, whether established in vivo through active immunization, or transferred adoptively after ex vivo expansion, will likely only encounter the native sequence. This allows the CTLs to be maintained over an extended duration in vivo.

One of the original reasons for selecting and testing CAP1 was its non-identity with other reported sequences in the human genome. It was therefore predicted that any immune responses attained would be unlikely to damage normal tissues bearing other antigens. For this reason a similar search of protein databases was undertaken for the peptides CAP1-6D and CAP1-7I and revealed that they are not reported as human sequences elsewhere in the Genbank (Genetics Computer Group, Madison, WI). However, two similar sequences, YLNVQDLNL (SEQ. ID No: 9) and YLHDPEFNL (SEQ. ID No: 10), are reported for antigens from African swine fever virus and measles virus, respectively. These sequences fit the consensus motif for HLA-A2 and therefore allow infected individuals to express cross-reacting antigens to CAP1. One interesting possibility is that the presence of anti-CAP1 CTL in some patients represents an example of epitope mimicry (50).

Two recent reports suggest that modified asparagine residues might enhance the immunogenicity of class I MHC peptides. Skipper et al. (40) used CTL generated in mixed lymphocyte tumor cell cultures to

-27-

identify antigens in extracts of melanoma cells. One antigenic peptide was identical at 8 of 9 positions to a sequence from tyrosinase, with an asparagine to aspartic acid replacement at position 3. When tested using synthetic peptides, the CTL were more active against the aspartic acid peptide than against the peptide containing the genetically predicted asparagine. These authors speculate that post-translational deamidations can generate antigenic peptides from normal differentiation antigens. Recently, Chen et al. (51) reported generating murine CTL to a stabilized succinimide derivative of an asparagine-containing antigenic peptide. Although these CTL could kill targets pulsed with the natural asparagine peptide, they did so with less sensitivity. They raise the possibility that deamidation of proteins in vivo and in vitro can produce transient succinimide intermediates that represent altered self-ligands capable of eliciting an immune response. At the other extreme, Kersh and Allen (52) replaced a TCR contact asparagine with aspartic acid in a hemoglobin peptide and abolished responsiveness to a murine Th clone. Presently we cannot exclude the possibility that the enhanced reactivity of CAP1-6D is due to deamidation of the native sequence which in turn primes the response that we detect with CAP1. However, our repeated inability to raise anti-CAP1 CTL from pre-immunized PBMC of the same patients from whom we generated post-immunization CTL, argues against this. Also, putative deamidations could not account for the recognition of other analogs such as CAP1-6C or CAP1-7I by T-Vac8 CTL. Instead it seems more reasonable that T cell receptors from both T-Vac8 and T-Vac24, as well as the new

-28-

lines described here, can recognize some deviation from the native CAP1 sequence.

In summary, synthesis of analogs of an immunodominant CEA peptide with amino acid substitutions at positions predicted to potentially interact with the T cell receptor allowed us to identify an enhancer agonist. This agonist was recognized by two different CEA CTL and increases the activity of one of them by 2-3 orders of magnitude. The agonist was also able to stimulate growth of CTL from peripheral blood of non-immunized normal donors with far greater facility than the native peptide sequence. Most important, the CTL generated using the enhancer agonist was able to recognize and lyse targets presenting the native sequence, including tumor cell lines expressing endogenous CEA. In accordance with the present invention, characterization of this enhancer agonist peptide facilitates more aggressive anti-tumor immunotherapies when employed as an immunogen in vivo, or for the ex vivo expansion of autologous anti-tumor CTL. The synthetic approach employed according to the present invention is also useful in improving immunogenicity of other peptide CTL epitopes.

#### MATERIALS AND METHODS

##### PEPTIDES

A panel of single amino acid substitutions to positions p5 through p8 of the CEA peptide CAP1 were made by f-moc chemistry using pin technology (Chiron Mimotopes, Victoria, Australia). CAP1 (YLSGANLNL) and CAP1-6D (YLSGADLNL), greater than 96% pure, were also made by Multiple Peptide Systems (San Diego, CA). Additional peptides CAP1-7I and NCA571 were synthesized on an Applied

-29-

10 Biosystems 432A synthesizer and were greater than 90% pure by C18 reverse-phase HPLC.

#### CELL LINES

5 T-Vac8 (53) and T-Vac24 (11) are human CTL specific for the CEA peptide CAP1. These cell lines were generated by in vitro stimulation of PBMC using CAP1 and IL-2, according to previously published methods (11). Briefly, post-immunization PBMC were from HLA-A2+ individuals with advanced carcinoma that had been administered rV-CEA in a Phase I trial. PBMC were isolated on gradients of lymphocyte separation medium (Organon Teknika, Durham, NC) and  $2 \times 10^5$  cells were placed in wells of sterile 96 well culture plates (Coming Costar, Cambridge, MA) along with 50  $\mu$ g/ml peptide. After 5 days incubation at 37°C in a humidified atmosphere containing 5% CO<sub>2</sub>, supernatants were removed and replaced with medium containing 10 U/ml human IL-2 (a gift of the Surgery Branch, NCI). Cultures were fed with IL-2 every 3 days for 11 days and then restimulated with irradiated (4000 rad) autologous PBMC ( $5 \times 10^5$ ) and peptide. Fresh IL-2 was provided every third day and subsequent restimulations were done every 2 weeks. CTL are maintained in complete RPMI (GIBCO/BRL, Grand Island, NY) medium with glutamine (GIBCO/BRL), penicillin, streptomycin and 10% pooled human AB serum (Gemini Bioproducts, Inc., Calabasas, CA).

30 Cell line C1R-A2 (provided by Dr. W. Biddison, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD) is maintained in complete RPMI with 10% fetal bovine serum (FBS, Biofluids Inc., Rockville, MD), glutamine, non essential

35

-30-

o amino acids and pyruvate (Biofluids) and 1 mg/ml G418.  
Cell line 174.CEM-T2 (provided by Dr. P. Creswell, Yale  
University School of Medicine, New Haven, CT) is defective  
in endogenous peptide processing and is maintained in  
Iscove's (GIBCO/BRL) with 10% FBS. Both C1R-A2 and T2  
5 lines present exogenous peptides with HLA-A2.

CEA positive tumor cell lines SW480, SW1463,  
SW1116 and SW 837 were obtained from the American Type  
Culture Collection (ATCC, Rockville, MD) and passaged  
10 weekly in respective culture medium described in the ATCC  
catalog. The CEA negative melanoma line SKmel24 (provided  
by Dr. S. Rosenberg, National Cancer Institute, National  
Institutes of Health, Bethesda, MD) was passaged weekly in  
RPMI 1640, 10% FBS and 10 µg/ml gentamicin (Life  
15 Technologies). The CEA negative ovarian tumor CaOV3 was  
provided by Dr. R. Freedman (MD Anderson Cancer Center,  
Houston TX) and was cultured in RPMI with 15% FBS,  
glutamine, 12 µg/ml insulin (Sigma, St. Louis, MO), 10  
20 µg/ml hydrocortisone (Biofluids) and 10 µg/ml gentamicin.  
All tumor lines were trypsinized with Trypsin/Versene  
(Biofluids) for 5-10 minutes prior to labeling with  
isotope for CTL assays. The highly sensitive natural  
25 killer (NK) target K562 was obtained from ATCC and  
passaged weekly with RPMI 1640, 10% FBS.

#### GENERATION OF CTL

30 T cell lines T-N1 and T-N2 were generated from  
PBMC of two normal HLA-A2 positive donors by in vitro  
stimulation with peptide as follows. For the first  
stimulation cycle, T cells were positively selected by  
panning on CD3+ MicroCollector flasks (Applied Immune  
35



-31-

Sciences, Santa Clara, CA). CD3+ cells ( $3 \times 10^6$ ) were cultured with  $10^6$  174.CEM-T2 cells that were previously infected with vaccinia virus expressing human B7 at a multiplicity of infection of 10, pulsed with 50  $\mu\text{g/ml}$  CAP1 or CAP1-6D peptide and 2  $\mu\text{g/ml}$  human  $\beta 2$  microglobulin (Intergen, Purchase, NY), and irradiated (10,000 rad). Cultures were incubated at 37°C in a humidified atmosphere containing 5% CO<sub>2</sub>, in T25 flasks in RPMI with 10% human serum, 2 mM glutamine, and 10  $\mu\text{g/ml}$  gentamicin in a total volume of 10 ml with  $2 \times 10^7$  irradiated (2500 rads) autologous PBMC as feeder cells. After 24 hours in culture 10 U/ml hIL-2 and 0.1 ng/ml rIL-12 (R & D Systems, Minneapolis, MN) were added. After 9 days in culture, cells were restimulated using irradiated (10,000 rads) autologous EBV-B cells preincubated with 25  $\mu\text{g/ml}$  peptide at a ratio of 2.5:1 stimulator cells to T cells, and IL-2 and IL-12 were again added 24 hours later. Peptide concentration was halved with each subsequent stimulation cycle until a final concentration of 3.12  $\mu\text{g/ml}$  was achieved.

In addition, CTL were generated from post-immunization PBMC of cancer patient Vac8 by stimulation with CAP1-6D according to already published procedures (11).

#### CTL ASSAY

Target cells were labeled with  $^{51}\text{Cr}$  or  $^{111}\text{In}$ , then incubated at 2,000-10,000 per well with or without peptides in round bottom microtiter plates (Corning Costar). One hour later, T cells were added. Supernatants were harvested (Skatron, Inc., Sterling VA)

-32-

after 4 hour and isotope release was measured. All assays were performed in triplicate and percent specific release was calculated according to:

$$\frac{(\text{observed release-spontaneous release})}{(\text{maximum release-spontaneous release})} \times 100$$

where spontaneous release is obtained by omitting the T cells, and maximum release is obtained by adding 1% Triton X100.

#### BINDING ASSAY

Binding of peptides to HLA-A2 was evaluated by incubation with processing defective 174.CEM-T2 cells and measuring the stability of cell surface peptide-A2 complexes (30). Briefly, cells were harvested and washed with serum-free RPMI then incubated overnight at  $1-2 \times 10^6$  cells/well with various concentrations of peptides. The next day, cells were collected, washed in PBS with  $\text{Ca}^{2+}$ ,  $\text{Mg}^{2+}$  and 5% FBS, then divided into aliquots for single color flow cytometric analysis. Cells were incubated 1 hour on ice without antibody, with anti-A2 antibody A2,69 (One Lambda, Inc., Canoga Park, CA) or with isotype-matched control antibody UPC-10 (Organon Teknika) then washed and stained 1 hour with fluorescein-isothiocyanate (FITC) goat anti-mouse Ig (Southern Biotechnology Associates, Birmingham, AL). Cell surface staining was measured in a Becton Dickinson flow cytometer (Mountain View, CA) and the mean fluorescence intensity (MFI) for 10,000 live cells was plotted against peptide concentration.

-33-

TCR CHAIN USAGE

T-N1 CTL were cultured as described for 5 cycles of antigenic stimulation using the CAP1-6D analog. The line was then split and duplicate cultures were maintained either with CAP1 or CAP1-6D for 5 additional stimulation cycles. Ficoll-purified T cells ( $5 \times 10^5$ ) were stained with a panel of 19 anti-V $\beta$  and 2 anti-V $\alpha$  murine monoclonal antibodies to human  $\alpha\beta$  T cell receptor variable regions. Cells were incubated with 10  $\mu\text{g/ml}$  of purified antibodies for 30 minutes at 4°C. The unlabeled monoclonals used were: V $\beta$ 3.1 clone 8F10, V $\beta$ 5(a) clone 1C1, V $\beta$ 5(b) clone W112, V $\beta$ 5(c) clone LC4, V $\beta$ 6.7 clone OT145, V $\beta$ 8(a) clone 16G8, V $\beta$ 12 clone S511, V $\beta$ 13 clone BAM13, V $\alpha$ 2 clone F1 and V $\alpha$ 12.1 clone 6D6 (T Cell Diagnostics, Woburn, MA) and V $\beta$ 18 (Immunotech, Westbrook, ME). Cells were stained with 10  $\mu\text{g/ml}$  of FITC-labeled goat anti-mouse IgG antibody (Southern Biotechnology Associates) for 30 minutes in the dark. Directly labeled monoclonals were: FITC-labeled V $\beta$ 11, V $\beta$ 21.3, V $\beta$ 13.6, V $\beta$ 14, V $\beta$ 16, V $\beta$ 17, V $\beta$ 20 and V $\beta$ 22 and PE-labeled V $\beta$ 9 and V $\beta$ 23 (Immunotech). Cells were fixed with 1% paraformaldehyde, washed with FACSFlow buffer (Becton Dickinson) and analyzed using a Becton Dickinson flow cytometer.

EXAMPLESCAP1 Substituted Peptides

Several factors were considered in deciding which positions to examine for effects on T cell activity. Sequencing and mapping experiments have defined a binding motif in which position 2 and the C-terminal (position 9 or 10) are critical for peptide presentation by HLA-A2

-34-

(for review, see 31). In addition, Tyr at position 1 has been identified as an effective secondary anchor (20, 32). Since the CEA peptide CAP1 already has the preferred amino acids at these three positions these residues were not altered. Instead, we focused attention on residues predicted to interact with the TCR in the hope of finding analogs that would stimulate human CAP1-specific cytotoxic T cells. X-ray crystallographic studies of several peptides bound to soluble HLA-A2 suggest that all binding peptides assume a common conformation in the peptide binding groove (33). When five model peptides were examined, residues 5 through 8 protrude away from the binding groove and are potentially available for binding to a TCR. Therefore a panel of 80 CAP1 analog peptides was produced in which the residues at positions 5 through 8 (p5-p8) were synthesized with each of the 20 natural amino acids. The peptides are designated CAP1-pAA, where p refers to the position in the peptide and AA refers to the replacement amino acid, using the single letter amino acid code; i.e., CAP1-6D in which position 6 is occupied by aspartic acid.

#### Enhanced CTL Sensitivity of Targets to CAP1-6D Analog

The effects of these amino acid substitutions on potential TCR recognition was studied using a CAP1 specific, HLA-A2 restricted human CTL line designated T-Vac8. Briefly, T-Vac8 was generated as described in Materials and Methods by in vitro peptide stimulation of PBMC from a patient that had been administered rV-CEA. For initial screening, T-Vac8 was used in a cytotoxicity assay to measure <sup>111</sup>In release from labeled C1R-A2 cells

35

-35-

incubated with each member of the peptide panel (at three peptide concentrations). Spontaneous release from the targets (in the absence of T-Vac8) was determined for each individual peptide.

The results are presented in Figure 1A through 1D. Of the 80 single amino acid substitutions, most failed to activate cytotoxicity of T-Vac8. However, six independent substitutions preserved reactivity. At position 5, three analogs CAP1-5F, CAP1-5I and CAP1-5S provided stimulation, albeit at reduced levels compared to CAP1 itself. At position 6 the substitutions CAP1-6C and CAP1-6D activated T-Vac8 cytotoxicity and seemed to be equal to or better than CAP1 since they were more active at the intermediate (0.1  $\mu\text{g/ml}$ ) peptide concentration. At position 7 analog CAP1-7I also appeared to be active. Finally, at position 8, no analogs were able to sensitize targets to lysis by T-Vac8. The two most active analogs (CAP1-6D and CAP1-7I) were then analyzed in detail, omitting CAP1-6C due to concern for disulfide formation under oxidizing conditions.

Purer preparations (90-96% pure) of native CAP1 and the analogs CAP1-6D and CAP1-7I were synthesized and compared in a CTL assay over a wider range of peptide concentrations, using two different cell lines as targets (Figure 2A and 2B). Employing T2 cells analog CAP1-6D was at least  $10^2$  times more effective than native CAP1. CAP1-6D lytic activity was at 1/2 maximum at  $10^{-4}$   $\mu\text{g/ml}$  (Figure 2A). In contrast, the CAP1-7I analog and the native CAP1 sequence were comparable with each other over the entire range of peptide titration and showed half maximal lysis at  $10^{-2}$   $\mu\text{g/ml}$ . Employing the C1R-A2 cells

-36-

as targets, CAP1-6D was similarly between  $10^2$  and  $10^3$  more effective in mediating lysis than CAP1 (Figure 2B).

The CAP1-6D peptide was also tested using a second CEA-specific T cell line, T-Vac24 (11). This line was generated from rV-CEA post vaccination PBMC of a different carcinoma patient by in vitro stimulation with the native CAP1 peptide; in contrast to predominantly CD8+ T-Vac8, T-Vac24 has a high percentage of CD4+CD8+ double positive cells (11). In a 4 hr  $^{111}\text{In}$  release assay employing T-Vac24, CAP1-6D was slightly more effective (30% lysis) than the native CAP1 sequence (20% lysis); although the differences were not as pronounced as with T-Vac8, the increased sensitivity to the analog was seen in three separate experiments. The analog peptide clearly engaged the lytic apparatus of a second CAP1 specific CTL.

#### Analogues and Native Peptide Show Identical Presentation by HLA-A2

The increased effectiveness of CAP1-6D in CTL assays could be due to better presentation by the target. The most active CAP1 analogs were tested for binding to HLA-A2 by measuring cell surface HLA-A2 in the transport-defective human cell line T2. When compared over a 4-log range of concentrations, native CAP1 and the two analogs CAP1-6D and CAP1-7I all presented equally on T2 cells (Figure 3). In addition, dissociation experiments indicate that the HLA-A2 complexes that form with the 3 peptides show no appreciable differences in stability (Figure 3 - insert). When peptide-pulsed T2 cells were washed free of unbound peptide, the half lives of cell surface peptide-A2 complexes were 12.5 hrs (CAP1),

-37-

9.7 hrs (CAP1-6D), and 10.8 hrs (CAP1-71). If anything, the complex formed with the agonist peptide seems slightly less stable. Since there are no differences in binding to HLA-A2, the improved effectiveness of CAP1-6D in the CTL assays appears to be due to better engagement by the T cell receptor, a behavior characteristic of an enhancer agonist peptide.

Human CTL Generated With CAP1-6D Also Recognize Native CAP1

The CAP1-6D agonist might be useful in both experimental and clinical applications if it can stimulate growth of CEA-specific CTL from patients with established carcinomas. In one experiment, post rV-CEA immunization PBMC from cancer patient Vac8 (the same rV-CEA patient from whom T-Vac8 CTL were established) were stimulated in vitro with CAP1-6D and after 5 rounds of stimulation were assayed for CTL activity against targets coated with CAP1 or CAP1-6D. This new line demonstrated peptide-dependent cytotoxic activity against target cells coated with either CAP1-6D or native CAP1 (Table 1).

Post immunization PBMC from patients Vac8 and Vac24 were already shown to produce CTL activity when stimulated with CAP1 while preimmunization PBMC were negative (11, 34). Moreover, previous attempts to stimulate CTL activity from healthy, non-immunized donors with the CAP1 peptide were unsuccessful. To test if the agonist peptide is indeed more immunogenic than native CAP1 we attempted to generate CTL from healthy, non-immunized donors using CAP1-6D. HLA-A2+ PBMC from apparently healthy individuals were stimulated in vitro

-38-

either with CAP1 or the CAP1-6D agonist. After 4 cycles of in vitro stimulation, cell lines were assayed for specificity against C1R-A2 cells pulsed with either CAP1 or CAP1-6D.

While stimulations with CAP1 or the CAP1-6D peptide produced T cell lines, peptide specific lysis was only obtained in the lines generated with CAP1-6D. Two independent T cell lines from different donors were derived using CAP1-6D and were designated T-N1 and T-N2 (Figure 4A and Figure 4B respectively). Both CTL lines lyse C1R-A2 targets pulsed with native CAP1 peptide. However, more efficient lysis is obtained using the CAP1-6D agonist. T-N1 CTL recognizes CAP1-6D at a 3-10 fold lower peptide concentration than CAP1 and T-N2 recognizes the agonist 100 fold better than CAP1. In contrast, attempts to generate a CTL cell line from normal donors by stimulation with CAP1 resulted in lines with no peptide-dependent lysis and loss of the lines in early stimulation cycles. Thus the attempts to generate T cell lines using the two peptides demonstrated the ability of CAP1-6D to act as an agonist not only at the effector stage, in the lysis of targets, but also in selecting T cells that are presumably in low precursor frequencies.

To determine whether CTL established with the agonist could be maintained on the native CAP1 sequence, T-N1 was cultured for 5 cycles as described using CAP1-6D, then divided into duplicate cultures maintained on the agonist or on CAP1. T-N1 continued to grow when stimulated with either peptide and responded to both peptides in CTL assays. Phenotypic analysis of the TCR usage in T-N1 indicates that the majority of cells (71%)



-39-

utilize V $\beta$ 12, with a minor population that utilize V $\beta$ 5.3 (Table 2). The same pattern of TCR V $\beta$  usage was observed after switching the cells to CAP1 for 5 more stimulation cycles. This V $\beta$  usage pattern was distinct from that of T-Vac8. These data indicate that the agonist can select T cells that are probably in low precursor frequency but that once selected, such CTL could be maintained with the native CAP1.

10 CTL Generated With CAP1-6D Specifically Lysed CEA<sup>+</sup>,HLA-A2<sup>+</sup> Tumor Cells

Studies were conducted to determine the ability of CTL generated with the enhancer agonist to lyse human tumor cells endogenously expressing CEA. T-N1 and T-N2 were tested against a panel of tumor cells that are CEA<sup>+</sup>/A2<sup>+</sup> (SW480 and SW1463), CEA<sup>+</sup>/A2<sup>-</sup> (SW1116) or CEA<sup>-</sup>/A2<sup>+</sup> (CaOV3 and SKmel24). A T cell line (T-N2) from the normal donor was tested for the ability to lyse tumor targets endogenously expressing CEA. T-N2 CTL generated with the agonist lysed tumor cells expressing both CEA and HLA-A2 while exhibiting no titratable lysis of CEA<sup>-</sup>/A2<sup>+</sup> SKmel24 melanoma cells (Figure 5A). No significant lysis of K562 was observed. In contrast, cell lines generated by stimulation with native CAP1 showed no detectable antitumor activity (Figure 5B). The HLA-A2.1 restriction of the T-N2 response to CEA positive tumor targets was further demonstrated by the specific lysis of a CEA positive HLA-A2.1 negative tumor cell, SW837 after infection with a vaccinia-A2.1 construct (rV-A2.1). No lysis was observed when SW837 targets were infected with the control wild type vaccinia without the A2.1 transgene

-40-

(Figure 6).

The ability of a CTL line (T-N1) derived from a second donor to kill carcinoma targets expressing endogenous CEA is shown in Figure 7A and 7B. T-N1 specifically lysed SW480 tumor cells. This is dramatically enhanced to 79% lysis by pretreatment of the tumor cells with IFN- $\gamma$ , a treatment that increases the cell surface density of both HLA-A2 and CEA. The specificity of T-N1 killing is demonstrated by its inability to lyse CEA<sup>-</sup>/A2<sup>+</sup> tumors such as the ovarian derived tumor CaOV3, the melanoma tumor SKmel24, or the NK target K562. Finally, restriction by HLA-A2 is demonstrated by the failure of T-N1 to lyse CEA<sup>+</sup>/A2<sup>-</sup> SW1116 tumor cells (Figure 7A), even after IFN- $\gamma$  treatment (Figure 7B).

Table 1: CTL generated by stimulation with the CAP1-6D analog from PBMC of an HLA-A2 patient immunized with rVCEA

Effector/target ratio	% Lysis		
	no peptide	CAP1	CAP1-6D
25:1	10%	41%	40%
6.25:1	0.5%	38%	46%

T cells were assayed after 5 in vitro stimulations. Cytotoxic activity was determined in 4 hour release assay with peptide at 25  $\mu$ g/ml.

-41-

Table 2: TCR usage of CTL line established on CAP1-6D agonist

5	TCR usage <sup>a</sup>	T-N1 <sup>b</sup>		T-N1 <sup>c</sup>	
		% positive	MFI	% positive	MFI
	V $\beta$ 12	71	83	70	83
	V $\beta$ 5.3	18	47	20	57
10	V $\beta$ 3.1	6	48	8	46
	V $\beta$ 8	3	30	6	26
	V $\beta$ 13.6	2	19	3	39
15	V $\beta$ 12.1	3	43	3	40

<sup>a</sup> Determined by FACS analysis using a panel of 19 V $\beta$  and 2 V $\alpha$  antibodies (see Materials and Methods). Only positively staining antibodies are shown.

20 <sup>b</sup> CTL line selected and maintained on agonist CAP1-6D as described in the Materials and Methods section.

<sup>c</sup> CTL line selected on agonist CAP1-6D for 5 stimulation cycles, and maintained on CAP1 for an additional 10 cycles.

25 This invention has been described in detail including preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of this disclosure, may make modifications and improvements thereon without departing from the spirit and scope of the invention.

30

References referred to are incorporated herein by reference.

-42-

REFERENCES

1. Muraro, R., Wunderlich, D., Thor, A.,  
Lundy, J., Noguchi, P., Cunningham, R., and Schlom, J.  
Definition by monoclonal antibodies of a repertoire of  
epitopes of carcinoembryonic antigen differentially  
expressed in human colon carcinoma versus normal adult  
tissues. Cancer Res., 45: 5769-5780 1985.
2. Steward, A.M., Nixon, D., Zamcheck, N., and  
Aisenberg, A. Carcinoembryonic antigen in breast cancer  
patients: serum levels and disease progress. Cancer, 33:  
1246-1252, 1974.
3. Vincent, R.G. and Chu, T.M.  
Carcinoembryonic antigen in patients with carcinoma of the  
lung. J. Thor. Cardiovas. Surg., 66: 320-328, 1978.
4. Gold, J.M., Freedman, S.O., and Gold, P.  
Human anti CEA antibodies detected by  
radioimmuno-electrophoresis. Nature New Biology, 239:  
60-62. 1973.
5. Pompecki, R. Presence of immunoglobulin G  
in human sera binding to carcinoembryonic antigen (CEA)  
and nonspecific crossreacting antigen (NCA). Eur. J  
Cancer, 16: 973-974, 1980.
6. Ura, Y., Ochi, Y., Hamazu, M., Ishida, M.,  
Nakajima, K., and Watanabe, T. Studies on circulating  
antibodies against CEA and CEA like antigen in cancer  
patients. Cancer Lett., 25: 283-295, 1985.

-43-

7. Fuchs, C., Krapf, F., Kern, P.,  
Hoferichter, S., Jager, W., and Kalden, J.R. CEA-  
containing immune complexes in sera of patients with  
colorectal and breast cancer-analysis of complexed  
immunoglobulin classes. Cancer Immunol. Immunother.,  
26:180-184, 1988.
8. LoGerfo, P., Herter, F.P., and Bennett, S.J.  
Absence of circulating antibodies to carcinoembryonic  
antigen in patients with gastrointestinal malignancies.  
Int. J. Cancer, 9: 344-348. 1972.
9. MacSween, J.M. The antigenicity of  
carcinoembryonic antigen in man. Int. J. Cancer, 15:  
246-252. 1975.
10. Chester, K.A. and Begent, H.J. Circulating  
immune complexes (CIC), carcinoembryonic antigen (CEA) and  
CIC containing CEA as markers for colorectal cancer.  
Clin. Exp. Immunol., 58: 685-693, 1984.
11. Tsang, K Y., Zaremba, S., Nieroda, C.A.,  
Zhu, M.Z, Hamilton, J.M., and Schlom, J. Generation of  
human cytotoxic T cells specific for human  
carcinoembryonic antigen epitopes from patients immunized  
with recombinant vaccinia-CEA vaccine. J. Natl. Cancer  
Inst., 87: 982-990. 1995.
12. Gadea, J., Brunette, E., Philip, M., Lyeriy,  
H.K., Philip, R., and Alters, S. Generation of antigen

-44-

- specific CTL using peptide and gene modified dendritic cells. Proc. Am. Assoc. Cancer Res. [abstr], 3154. 1996.
13. Marshall, J.L., Hawkins, M.J., Richmond, E., Tsang, K., and Schlom, J. A study of recombinant ALVAC-CEA in patients with advanced CEA-bearing cancers. J. Immunol. [abstr]. 19: 461. 1996.
14. Foon, K.A., Chakraborty, M., John, W.J., Sherratt, A., Kohler, H., and Bhattacharya-Chatterjee, M. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotypic antibody vaccine. J. Clin. Invest., 96: 334-342, 1995.
15. Fagerberg, J., Samanci, A., Yi, Q., Strigard, K., Ryden, U., Wahren, B., and Mellstedt, H. Recombinant carcinoembryonic antigen and granulocyte-macrophage colony-stimulating factor for active immunization of colorectal carcinoma patients. J. Immunol. [abstr]. 19: 461. 1996.
16. Conry, R.M., Saleh, M.N., Schlom, J., and LoBuglio, A.F. Human immune response to carcinoembryonic antigen tumor vaccines. J. Immunother. [abstr], 18: 137, 1995.
17. Parkhurst, M.R., Salgaller, M.L., Southwood, S., Robbins, P.F., Sette, A., Rosenberg, S A., and Kawakami, Y. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A\*0201-binding residues. J. Immunol., 157: 2539-2548,

-45-

o 1996.

18. Salgaller, M.L., Marincola, F.M., Cormier, J.N., and Rosenberg, S.A. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res., 56: 4749-4757, 1996.

10 19. Bakker, A.B.H., van der Burg, S.H., Huubens, R.J.F., Drijfhout, J.W., Melief, C.J., Adema, G.J., and Figdor, C.G. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild type epitope. Int. J. Cancer, 70: 302-309, 1997.

15 20. Pogue, R.R., Eron, J., Frelinger, J.A., and Matsui, M. Amino-terminal alteration of the HLA-A\*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc. Nat. Acad. Sci., 92: 8166-8170, 1995.

25 21. Lipford, G., Bauer, S., Wagner, H., and Heeg, K. Peptide engineering allows cytotoxic T cell vaccination against human papilloma virus tumor antigen E6. Immunol., 84: 298-303. 1995.

30 22. Grey, H.M., Ruppert, J., Vitiello, A., Sidney, J., Kast, W.M., Kubo, R.T., and Sette, A. Class I MHC-peptide interactions: structural requirements and functional implications. Cancer Surv., 22: 37-49, 1995.

35

-46-

23. De Magistris, M.T., Alexander, J.,  
Coggeshall, M., Altman, A., Gaeta, F.C A., Grey, H.M., and  
Sette, A. Antigen analog-major histocompatibility  
complexes act as antagonists of the T cell receptor.  
5 Cell, 68: 625-634. 1992.
24. Bertoletti, A., Sette, A., Chissari, F.V.,  
Penna, A., Levrero, M., Carli, M.D., Fiaccadori, F., and  
10 Ferrari, F. Natural variants of cytotoxic epitopes are T  
cell receptor antagonists for antiviral cytotoxic T cells.  
Nature, 369: 407-410, 1994.
25. Klenerman, P., Rowland-Jones, S., McAdam, S.,  
15 Edwards, J., Daenke, S., Lalloo, D., Koppe, B., Rosenberg,  
W., Boyd, D., Edwards, A., Giangrande, P., Phillips, R.E.,  
and McMichael, A.J. Cytotoxic T cell activity antagonized  
by naturally occurring HIV-1 gag variants. Nature. 369:  
20 403-407. 1994.
26. Kuchroo, V.K., Greer, J.M., Kaul, D.,  
Ishioka, G., Franco, A., Sette, A., Sobel, R A., and Lees,  
M.B. A single TCR antagonist peptide inhibits  
25 experimental allergic encephalomyelitis mediated by a  
diverse T cell repertoire. J. Immunol., 153: 3326-3336.  
1994.
27. Jameson, S.C. and Bevan, M.J. T cell  
30 receptor antagonists and partial agonists. Immunity, 2:  
1-11, 1995.



-47-

28. Meier, U-C., Klenerman, P., Griffin, P.,  
James, W., Koppe, B., Larder, B., McMichael, A., and  
Phillips, R. Cytotoxic T lymphocyte lysis inhibited by  
viable HIV mutants. *Science*. 270: 1360-1362. 1995.
29. Chen, Y., Matsushita, S., and Nishimura, Y.  
Response of a human T cell clone to a large panel of  
altered peptide ligands carrying single residue  
substitutions in an antigenic peptide: characterization  
and frequencies of TCR agonist and TCR antagonism with or  
without partial activation. *J. Immunol.*, 157: 3783-3790.  
1996.
30. Nijman, H.W., Houbiers, J.G., Vierboom,  
M.P., van der Hurg, S.H., Drijfhout, J.W., D'Amaro, J.,  
Kenemans, P., Melief, C.J., and Kast, W.M. Identification  
of peptide sequences that potentially trigger  
HLA-A2.1-restricted cytotoxic T lymphocytes. *Eur. J.*  
*Immunol.*, 23: 1215-1219, 1993.
31. Rammensee, H-G., Friede, T., and Stevanovic,  
S. MHC ligands and peptide motifs: first listing.  
*Immunogenetics*, 41: 178-228, 1995.
32. Ruppert, J., Sidney, J., Celis, E., Kubo,  
R.T., Grey, H.M., and Sette, A. Prominent role of  
secondary anchor residues in peptide binding to HLA-A2.1  
molecules. *Cell*, 74: 929-937. 1993.
33. Madden, D.R., Garboczi, D.N., and Wiley,  
D.C. The antigenic identity of peptide-MHC complexes: a

-48-

- o comparison of the conformations of five viral peptides presented by HLA-A2. Cell, 75: 693-708, 1993.

34. Hamilton, J.M., Chen, A.P., Nguyen, B., Grem, J., Abrams, S., Chung, Y., Kantor, J., Phares, J.C.,  
5 Bastian, A., Brooks, C., Morrison, G., Allegra, C.J., and Schlom, J. Phase I study of recombinant vaccinia virus (rV) that expresses human carcinoembryonic antigen (CEA) in adult patients with adenocarcinomas. Proc. Am. Soc. Clin. Oncol. [abstr], 961. 1994.

10

35. Abrams, S.I., Horan Hand, P., Tsang, K.Y., and Schlom, J. Mutant ras epitopes as targets for cancer vaccines. Semin. Oncol., 23: 118-134, 1996.

15

36. Elas, A.V., Nijman, H.W., Van Minne, C.E., Mourer, J.S., Kast, W.M., Melief, C.J.M., and Schrier, P.I. Induction and characterization of cytotoxic T  
20 lymphocytes recognizing a mutated p21 RAS peptide presented by HLA-A2010. Int. J. Cancer, 61: 389-396, 1995.

37. Houbiers, J.G.A., Nijman, H.W., van der Burg, S.H., Drijfhout, J.W., Kenemans, P., van de Velde, C.J.H., Brande, A., Momburg, F., Kast, W.M., and Melief, C.J.M. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild type p53.  
30 Eur. J. Immunol., 23:2072-2077, 1993.

38. Ropke, M., Regner, M., and Claesson, M.H. T cell mediated cytotoxicity against p53-protein derived

35

-49-

- peptides in bulk and limiting dilution cultures of healthy donors. Scand. J. Immunol., 42: 98-103, 1995.
39. Robbins, P.F., El-Gamil, M., Li, Y.F., Kawakami, Y., Loftus, D., Appella, E., and Rosenberg, S.  
5 A mutated  $\beta$ -catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med.. 183: 1185-1192, 1996.
40. Skipper, J.C.A., Hendrickson, R.C., Guiden, P.H., Brichard, V., van Pel, A., Chen, Y., Shabanowitz, J., Wolfel, T., Slingluff, C.L., Jr., Boon, T., Hunt, D.F., and Engelhard, V.H. An HLA-A2-restricted tyrosinase  
10 antigen on melanoma cells results from post-translational modification and suggests a novel pathway for processing  
15 of membrane proteins. J. Exp. Med., 183: 527-534, 1996.
41. Thompson, J.A., Grunert, F., and Zimmerman, W. Carcinoembryonic antigen gene family: molecular  
20 biology and clinical perspectives. J. Clin. Lab. Anal., 5: 344-366, 1991.
42. Van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T. A gene encoding an antigen recognized by  
25 cytotoxic T lymphocytes on a human melanoma. Science, 254: 1643-1647, 1991.
43. Kawakami, Y., Eliyahu, S., Delgado, C.H., Robbins, P.F., Rivoltini, L., Topalian, S.L, Miki, T., and Rosenberg, S.A. Cloning of the gene coding for a shared  
30  
35

-50-

human melanocyte antigen recognized by autologous T cells  
infiltrating into tumor. Proc. Natl. Acad. Sci., 91:  
3515-3519. 1994.

44. Peoples, G.E., Goedegebuure, P.S., Smith,  
5 R., Linehan, D.C., Yoshino, I., and Eberlein, T.J. Breast  
and ovarian cancer-specific cytotoxic T lymphocytes  
recognize the same HER2/neu-derived peptide. Proc. Nat.  
Acad. Sci.. 92: 432-436, 1995.

10 45. Matsuoka, T., Kohrogi, H., Ando, M.,  
Nishimura, Y., and Matsushita, S. Altered TCR ligands  
affect antigen-presenting cell responses: up regulation of  
IL-12 by analogue peptide. J. Immunol., 157:4837-4843.  
15 1996.

46. Ikagawa, S., Matsushita, S., Chen, Y-Z,  
Ishikawa, T., and Nishimura, Y. Single amino acid  
20 substitutions on a Japanese cedar pollen allergen (Cry j  
1)-derived peptide induced alterations in human T cell  
responses and T cell receptor antagonism. J. Aller. Clin.  
Immunol., 97: 53-64, 1996.

25 47. England, R.D., Kullberg, M.C., Cornette,  
J.L., and Berzofsky, J.A. Molecular analysis of a  
heteroclitic T cell response to the immunodominant epitope  
of sperm whale myoglobin: Implications for peptide partial  
30 agonists. J. Immunol., 155: 4295-4306, 1995.

48. Ropke, M., Hald, J., Guldberg, P., Zeuthen,  
J., Norgaard, L, Fugger, L., Svejgaard, A., Van Der Burg,

35

-51-

- o S., Nijman, H.W., Melief, C.J.M., and Claesson, M.H.  
Spontaneous human squamous cell carcinomas are killed by a  
human cytotoxic T lymphocyte clone recognizing a wild-type  
p53-derived peptide. Proc. Nat. Acad. Sci., 93:  
14704-14707, 1996.

5

49. Correale, P., Walmsley, K., Nieroda, C.,  
Zaremba, S., Zhu, M., Schlom, J., and Tsang, K.Y. In  
vitro generation of human cytotoxic T lymphocytes specific  
for peptides derived from prostate-specific antigen. J.  
10 Natl. Cancer Inst., 89: 293-300, 1997.

50. Wucherpfennig, K.W. and Strominger, J.L.  
Molecular mimicry in T cell-mediated autoimmunity: viral  
15 peptides activate human T cell clones specific for myelin  
basic protein. Cell, 80: 695-705, 1995.

51. Chen, W., Ede, N.J., Jackson, D.C.,  
20 McCluskey, J., and Purcell, A.W. CTL recognition of an  
altered peptide associated with asparagine bond  
rearrangement: Implications for immunity and vaccine  
design. J. Immunol., 157: 1000-1005, 1996.

- 25 52. Kersh, G.J. and Allen, P.M. Structural  
basis for T cell recognition of altered peptide ligands: A  
single T cell receptor can productively recognize a large  
continuum of related ligands. J. Exp. Med 184: 1259-1268,  
30 1996.

53. Tsang, K.Y. Zhu, M.Z. Nieroda, C.A,  
Correale, P., Zaremba, S., Hamilton, J.M., Cole, D., Lam,

35

-52-

o C., and Schlom, J. Phenotypic Stability of a Cytotoxic T  
Cell Line Directed Against an Immunodominant Epitope of  
Human Carcinoembryonic Antigen (accepted by Clinical  
Cancer Res.).

5

10

15

20

25

30

35

-53-

We claim:

1. A peptide comprising an agonist of a native sequence:

YLSGANLNL (Seq. ID No: 1)

5       |       |  
      123456789

2. The peptide according to claim 1 wherein the agonist varies in an amino acid substitution at position 6 from Seq. ID No: 1.

10       3. The peptide according to claim 1 wherein the agonist varies in an amino acid substitution at position 7 from Seq. ID No: 1.

15       4. The peptide according to claim 1 wherein the agonist varies in an amino acid substitution at position 6 and position 7 from Seq. ID No: 1.

20       5. The peptide according to claim 1 containing YLSGADLNL (Seq. ID No: 2), YLSGADINL (Seq. ID No: 3), YLSGANINL (Seq. ID No: 4), YLSGACLNL (Seq. ID No: 5), or combination thereof.

25       6. A peptide consisting of the amino acid sequence YLSGADLNL (Seq. ID No: 2), YLSGADINL (Seq. ID No: 3), or YLSGANINL (Seq. ID No: 4), YLSGACLNL (Seq. ID No: 5).

7. A pharmaceutical composition comprising the peptide according to claim 1 and a pharmaceutically acceptable carrier.

30       8. The pharmaceutical composition according to claim 7 further comprising an immunostimulatory molecule.

9. The pharmaceutical composition according to claim 8 wherein the immunostimulatory molecule is selected from the group consisting of IL-2, B7.1, B7.2, ICAM-1,

35

-54-

10 LFA-3, CD72, GM-CSF, TNF $\alpha$ , INF $\gamma$ , IL-12, IL-6 and combinations thereof.

10. The pharmaceutical composition according to claim 7 further comprising an HLA class I molecule or a cell expressing an HLA class I molecule.

5 11. The pharmaceutical composition according to claim 7 further comprising a chemotherapeutic drug, antibiotic, antiviral drug, antifungal drug, or cyclophosphamide.

10 12. The pharmaceutical composition according to claim 7 further comprising an adjuvant.

13. The pharmaceutical composition according to claim 12 wherein the adjuvant is selected from the group consisting of alum, incomplete Freund's adjuvant, QS21, and Ribi Detox<sup>TM</sup>.

14. A peptide-immunoglobulin conjugate comprising the peptide according to claim 1 and an immunoglobulin molecule.

20 15. The pharmaceutical composition according to claim 7 wherein the peptide is incorporated into a liposome.

25 16. A peptide-carrier molecule conjugate comprising the peptide according to claim 1 conjugated to a carrier molecule.

17. The peptide-carrier molecule conjugate according to claim 15 wherein the carrier molecule is selected from the group consisting of influenza peptide, tetanus toxoid, tetanus toxoid-CD4 epitope, Pseudomonas exotoxin A, poly-L-lysine, a lipid tail and an endoplasmic reticulum signal sequence.

30 18. A kit comprising the agonist peptide

35



-55-

according to claim 1 and a vector comprising a nucleic acid sequence encoding CEA.

19. The kit according to claim 18 further comprising an immunostimulatory molecule.

20. An isolated DNA comprising a nucleotide sequence encoding the peptide according to claim 1 or variants thereof.

21. An isolated DNA encoding a peptide containing Seq. ID No: 2, Seq. ID No: 3, Seq. ID No: 4, Seq. ID No: 5, or combinations thereof.

22. An isolated DNA comprising a nucleotide sequence of SEQ. ID No: 7 or 8.

23. A vector comprising the DNA of claims 20, 21 or 22.

24. The vector according to claim 23 wherein the vector is an E. coli plasmid, a Listeria vector, an orthopox virus, avipox virus, capripox virus, suipox virus, vaccinia virus, baculovirus, human adenovirus, SV40 or bovine papilloma virus.

25. The vector according to claims 23 or 24 further comprising a nucleotide sequence encoding at least one HLA class I molecule.

26. A host cell comprising the vector according to claim 23.

27. The host cell according to claim 26 wherein the host cell additionally expresses an HLA class I molecule.

28. The host cell according to claim 26 wherein the host cell is an antigen presenting cell.

29. The host cell according to claim 28 wherein the host cell is a dendritic cell.

-56-

30. A method for treating a host having a tumor expressing CEA or epitope thereof comprising introducing cytotoxic T lymphocytes specific for CEA or epitope thereof to the host and at a periodic interval thereafter introducing to the host an agonist peptide according to claim 1.

31. The method according to claim 30 wherein the peptide is selected from the group consisting of Seq ID Nos: 2, 3, 4, 5 or combination thereof.

32. A method of inhibiting a CEA epitope-expressing carcinoma cells in a patient comprising administering to said patient an effective amount of the peptide according to claim 1.

33. The method according to claim 32 further comprising administration of an immunostimulatory molecule.

34. The method according to claim 33 wherein the immunostimulatory molecule is selected from the group consisting of IL-2, B7.1, B7.2, ICAM-1, LFA-3, CD72, GM-CSF, TNF $\alpha$ , INF $\gamma$ , IL-12, IL-6 and combinations thereof.

35. The method according to claim 32 further comprising administration of an adjuvant.

36. The method according to claim 32 wherein the carcinoma cell is gastrointestinal, breast, pancreatic, bladder, ovarian, lung, or prostate carcinoma cells.

37. The method according to claim 32 further comprising the administration of a vector comprising the gene encoding CEA.

38. A method of inhibiting or killing CEA epitope-expressing carcinoma cells comprising:

35

-57-

- o A) generating CEA epitope or agonist peptide-specific cytotoxic T lymphocytes *in vitro* by stimulation of lymphocytes from a source with an effective amount of an agonist peptide according to claim 1 alone or in  
5 combination with an immunostimulatory molecule; and
- B) adoptively transferring the CEA epitope or agonist peptide-specific cytotoxic T  
10 lymphocytes alone or in combination with the agonist peptide into a mammal in an amount sufficient to inhibit or kill the CEA epitope expressing carcinoma cells.
39. A method of inhibiting or killing CEA  
15 epitope-expressing carcinoma cells in a mammal comprising:
- A) generating CEA epitope or agonist peptide-specific cytotoxic T lymphocytes *in vivo* by administration of an effective amount of a  
20 agonist peptide according to claim 1, an effective amount of a vector comprising a nucleic acid sequence encoding CEA or agonist peptide pulsed antigen presenting cells; and
- 25 B) at a periodic interval providing the agonist peptide according to claim 1 alone or in combination with an adjuvant; wherein the CEA epitope or agonist peptide-specific cytotoxic T lymphocytes so  
30 generated inhibit or kill CEA epitope-expressing carcinoma cells.
40. A peptide comprising an antagonist of a

-58-

native sequence: YLSGANLNL (Seq. ID No: 1) wherein the antagonist varies at at least one amino acid position from SEQ. ID No: 1 and the antagonist inhibits CEA-specific immune responses.

41. A pharmaceutical composition comprising the peptide according to claim 36 and a pharmaceutically acceptable carrier.

42. A method of inhibiting CEA-specific immune responses comprising administration of the peptide according to claim 40 in an amount effective to inhibit the CEA-specific immune responses.

43. The method according to claim 42 wherein cytotoxic T lymphocytes specific for CEA or epitopes thereof are inhibited.

15

20

25

30

35

1 / 8




FIG. 1A




FIG. 1B

2 / 8




FIG. IC




FIG. ID

3 / 8




FIG. 2A




FIG. 2B

4 / 8




FIG. 3A




FIG. 3B

SUBSTITUTE SHEET (RULE 26)



5 / 8




FIG. 4A




FIG. 4B

6 / 8




FIG. 5A




FIG. 5B




FIG. 6

8 / 8




FIG. 7A




FIG. 7B

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/19794

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 6 C12N15/12 C07K14/705 A61K38/17 A61K47/00 A61K35/14 A61K48/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N C07K A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	ZAREMBA S. ET AL.: "Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen" CANCER RESEARCH, vol. 57, no. 20, 15 October 1997, pages 4570-4577, XP002096107 see the whole document ---	1-7
A	WO 96 26271 A (THERION BIOLOGICS CORP (US); US GOVERNMENT; SCHLOM; PANICALI; TSANG) 29 August 1996  see abstract see page 4, line 1 - page 6, line 17 see page 12, line 1 - page 15, line 13 see page 62 - page 67; claims --- -/--	1,7-9, 12,13, 15,18, 19,30, 32-39
<div style="display: flex; justify-content: space-between;"> <span><input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.</span> <span><input checked="" type="checkbox"/> Patent family members are listed in annex.</span> </div>		
* Special categories of cited documents :		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search  <div style="text-align: center; font-weight: bold;">10 March 1999</div>		Date of mailing of the international search report  <div style="text-align: center; font-weight: bold;">25/03/1999</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  <div style="text-align: center; font-weight: bold;">Macchia, G</div>

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 98/19794

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>TSANG K.Y. ET AL.: "Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant Vaccinia-CEA vaccine"</p> <p>JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 87, no. 13, 5 July 1995, pages 982-990, XP000578019</p> <p>cited in the application</p> <p>see the whole document</p> <p style="text-align: center;">---</p>	<p>1,7-9, 12,13, 15,18, 19,30, 32-39</p>
A	<p>WO 92 19266 A (US GOVERNMENT; SCHLOM J.; KANTOR J.) 12 November 1992</p> <p>see page 10, line 14 - page 11, line 18</p> <p>see page 23, line 25 - page 26, line 5;</p> <p>examples 10,11</p> <p style="text-align: center;">---</p>	<p>8,9,11</p>
A	<p>CHEN Y.-Z. ET AL.: "Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide"</p> <p>THE JOURNAL OF IMMUNOLOGY, vol. 157, 1996, pages 3783-3790, XP002096108</p> <p>cited in the application</p> <p>see abstract</p> <p style="text-align: center;">---</p>	<p>40</p>
A	<p>JAMESON S.C. ET AL.: "T cell receptor antagonists and partial agonists"</p> <p>IMMUNITY, vol. 2, no. 1, January 1995, pages 1-11, XP000600494</p> <p>cited in the application</p> <p>see page 8 - page 9</p> <p style="text-align: center;">-----</p>	<p>40</p>

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 19794

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 30-39, 42, 43 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/19794

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9626271 A	29-08-1996	AU 5024096 A CA 2213451 A EP 0811062 A	11-09-1996 29-08-1996 10-12-1997
WO 9219266 A	12-11-1992	AU 674492 B AU 2006092 A CA 2102623 A EP 0584266 A JP 6508025 T US 5698530 A	02-01-1997 21-12-1992 07-11-1992 02-03-1994 14-09-1994 16-12-1997